Production (Stage)
Intellia Therapeutics, Inc.
NTLA
$8.26
$0.172.10%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -114.33M | -128.90M | -135.71M | -146.98M | -107.44M |
| Total Depreciation and Amortization | 2.50M | 2.57M | 2.61M | 2.60M | 2.51M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 21.69M | 39.10M | 38.33M | 56.57M | 13.99M |
| Change in Net Operating Assets | -58.78M | 2.04M | 9.94M | 29.62M | -29.73M |
| Cash from Operations | -148.93M | -85.20M | -84.84M | -58.19M | -120.66M |
| Capital Expenditure | -735.00K | -981.00K | -1.28M | -1.01M | -2.51M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.06M | 152.55M | -6.43M | -23.18M | 8.41M |
| Cash from Investing | 94.33M | 151.57M | -7.71M | -24.19M | 5.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 2.32M | 82.19M | 41.25M | 59.99M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 2.32M | 82.19M | 41.25M | 59.99M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -54.60M | 68.69M | -10.35M | -41.13M | -54.77M |